PHARMACEUTICAL COMBINATION FOR APPLICATION FOR INDUCING LOSS OF BODY WEIGHT IN SUBJECTS WITH TYPE 2 DIABETES OR / AND TO PREVENT A BODY WEIGHT SET IN SUBJECTS WITH TYPE 2 DIABETES

摘要

1. A pharmaceutical combination for use to improve glucose tolerance in subjects with type 2 diabetes, comprising: (a) desProExendin-4 (1-39) -Lys-NH or / and its pharmaceutically acceptable salt, and (b) metformin and / or its a pharmaceutically acceptable salt, wherein the subject to be treated is younger than 50 years old and has a plasma glucose concentration 2 hours after a meal of at least 14 mmol / L. 2. The pharmaceutical combination according to claim 1, wherein the subject to be treated has a glucose fluctuation of at least 2 mmol / L, at least 3 mmol / L, at least 4 mmol / L, or at least 5 mmol / L while the glucose fluctuation is the difference in plasma glucose concentration 2 hours after a meal and plasma glucose concentration 30 minutes before a test meal. 3. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is obese. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has a body mass index of at least 30 kg / m. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated is an adult. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated does not receive anti-diabetic treatment. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has been diagnosed with type 2 diabetes at least 1 year or at least 2 years before starting therapy. The pharmaceutical combination according to claim 1 or 2, wherein the subject to be treated has an HbA1c value of from about 7 to about 10% .9. Pharmaceutical Comb